Fully Invested in Collaboration

Our Partnerships

Each year, Launch Tx evaluates over one hundred projects, ranging from pioneering biotechs to established leaders among the top 10 pharmaceutical companies worldwide. Our objective: To cultivate impactful partnerships that enhance outcomes for all stakeholders. There is no strength without unity, which is why we are committed to working closely with selected partners, tailoring customized programs that comply with GAAP and IFRS accounting standards.

View Partnership Profiles

Explore our Partnership Profiles

Discover how the collaborative ventures with our partners are shaping the future of healthcare and biotechnology:

Teva + Launch Tx

Launch Therapeutics announces a co-development agreement with Teva to deliver Teva’s dual-action asthma rescue inhaler respiratory program
About Teva
  • Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing its generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine
  • The company’s global network of capabilities pushes the boundaries of scientific innovation to deliver quality medicines to help improve health outcomes of millions of patients every day
Deal Overview
  • Investors committed up to $150 million in funding to offset Teva’s ICS/SABA (TEV-‘248) program costs
Launch TX + Teva Collaboration
  • Launch Tx has the lead role in the operational execution and management of the planned clinical trials and Teva will retain primary responsibility for manufacturing, regulatory interactions in the U.S., and commercialization
  • Collaboration is supported by a Joint Steering Committee that includes executive leadership from both organizations
  • Launch Tx receives payment for performing services in accordance with the executed co-development agreement
TEV-‘248
  • Teva’s TEV-‘248 is a potentially best-in-class fixed dose combination of fluticasone propionate/albuterol sulfate in a multidose dry powder inhaler being developed for the reduction and prevention of asthma exacerbations
  • TEV-‘248 is currently in Phase 3 clinical trials to demonstrate a reduction in severe exacerbations compared to reliever treatment with albuterol alone (Study FpA-AS-30094) and the airway relaxation effect of albuterol in the combination product (Study FpA-AS-30093)

Gilead + Launch Tx

Launch Tx announces a strategic partnership with Gilead Sciences, establishing a Joint Steering Committee to support select clinical studies of TRODELVY®
About Gilead
  • Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people
  • The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer
  • Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California
Deal Overview
  • Investors committed up to $210 million in funding to support select clinical studies of Trodelvy® within non-small cell lung cancer

Launch TX + Gilead Collaboration
  • Launch Tx and Gilead have entered into a clinical collaboration agreement that establishes a Joint Steering Committee throughout the development of Trodelvy® in select clinical NSCLC studies
Trodelvy® (sacituzumab govitecan-hziy)
  • Trodelvy® (sacituzumab govitecan-hziy) is a first-in-class Trop-2-directed antibody-drug conjugate.
  • To learn more visit: TRODELVY.com

* The efficacy and safety of Trodelvy®  in NSCLC has not been established.

Pathalys + Launch Tx

Launch Tx forms strategic collaboration with Pathalys to advance PLS240, a novel calcimimetic to treat SHPT in patients with chronic kidney disease
Pathalys Background
  • Private, late-stage clinical biopharmaceutical company
  • Focused on the development of multiple advanced therapeutics that address unmet needs in the management of late-stage chronic kidney disease (CKD)
Deal Overview
  • Investors committed $150 million through a combination of secured product financing and equity to support the two Phase 3 clinical trials, registration efforts, and pre-commercialization activities for upacicalcet
Launch TX + Pathalys Collaboration
  • Launch Tx has the lead role in the operational execution and management of the clinical trials and Pathalys retains primary responsibility for manufacturing, FDA regulatory interactions, and commercialization
  • Collaboration is supported by an Executive Steering Committee that includes executive leadership from both
    organizations
  • Launch Tx receives payment for performing services in accordance with the executed co-development agreement
Global Phase 3 Program
  • Large global Phase 3 program of 2 identical studies underway in patients with secondary hyperparathyroidism (SHPT) and currently on hemodialysis
  • PATH-1 and PATH-2 (each trial will randomize approximately 375 patients (2:1) to upacicalcet or placebo: each study has 2 regions (NA and EU), 6 countries, 73 sites, and 10 vendors

Opthea + Launch Tx

Launch Tx collaborates with Opthea to advance OPT-302, a promising therapy for wet AMD
Opthea Background
  • Late-stage therapeutic development company listed on ASX and NASDAQ
  • Focused on developing novel therapies to treat highly prevalent and progressive retinal diseases
Deal Overview
  • Investors committed non-dilutive financing of up to $170 million to finance and advance the ongoing Phase 3 clinical trials and pre-commercialization activities of OPT-302
Launch TX + Opthea Collaboration
  • An initial development and commercial advisory partnership expanded into a formal services agreement whereby Launch Tx performs certain management and support services, such as CRO management
  • Collaboration is supported by a program governance model that includes senior and executive leadership from Launch Tx, Opthea, and the CRO
  • Opthea pays Launch Tx service fees for services provided by Launch Tx in accordance with the executed services agreement
Global Phase 3 Program
  • Large global Phase 3 program of 2 studies underway in patients with wet age-related macular degeneration (wet AMD)
  • ShORe (OPT-302 in combination with Ranibizumab): 4 regions (EU, LATAM, NA, APAC), 22 countries, ~200 sites, >900 patients, 14 vendors
  • COAST (OPT-302 in combination with Aflibercept): 4 regions, 30 countries, ~200 sites, >900 patients, 14 vendors